SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/6/2026 | Buy | TD Cowen | |
| 8/28/2024 | $12.00 | Buy | Guggenheim |
| 12/8/2023 | $11.00 | Outperform | Leerink Partners |
TD Cowen initiated coverage of Nanobiotix with a rating of Buy
Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00
Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00
Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company's other platformsNew data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung cancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy and Oncology (ESTRO)Announced FDA acceptance of a protocol amendment to ongoing pivotal J&J sponsored NANORAY-312 study eliminating the previously planned interim analysis and modifying the final analysis to include fewer events and to be conducted soonerPresented
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors. "Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities," said Laurent Levy, chief executive off
PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the "Closing") of its global offering (the "Global Offering"), including in respect of the earlier total exercise by the underwriters of their option (the "Option") to purchase additional new ordinary shares in the form of additional American Depositary Shares (the "Additional ADSs"). Following the full exercise of the Option, the total number of ordinary shares (e
6-K - Nanobiotix S.A. (0001760854) (Filer)
6-K - Nanobiotix S.A. (0001760854) (Filer)
6-K - Nanobiotix S.A. (0001760854) (Filer)
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the gl
PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors. "Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities," said Laurent Levy, chief executive off
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the
SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)
SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)
SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)